Douglas Emmett (DEI) 37.78 $DEI Douglas Emmett Sells

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Douglas Emmett (DEI) 37.78 $DEI

Douglas Emmett Sells Sherman Oaks Office Building For $56.7 Million
PR Newswire - Fri Sep 16, 3:54PM CDT
Douglas Emmett, Inc. (NYSEEI), a real estate investment trust (REIT), announced the closing of the previously announced sale of a 168,000 square foot office property in the Sherman Oaks neighborhood of Los Angeles for a contract price of $56.7 million in cash.
DEI: 37.78 (+0.03)

Douglas Emmett Declares Quarterly Cash Dividend
PR Newswire - Mon Sep 12, 3:15PM CDT
Douglas Emmett, Inc. (NYSE: DEI), a real estate investment trust (REIT), announced today that its Board of Directors has declared a quarterly cash dividend on each share of its common stock of $0.22, or $0.88 on an annualized basis. The dividend will be paid on October 14, 2016 to shareholders of record as of September 30, 2016.
DEI: 37.78 (+0.03)

Douglas Emmett Up 37.0% Since SmarTrend Uptrend Call (DEI)
Comtex SmarTrend(R) - Wed Sep 07, 1:23PM CDT
SmarTrend identified an Uptrend for Douglas Emmett (NYSEEI) on March 2nd, 2016 at $27.90. In approximately 6 months, Douglas Emmett has returned 36.96% as of today's recent price of $38.22.
DEI: 37.78 (+0.03)

33.8% Return Seen to Date on SmarTrend Douglas Emmett Call (DEI)
Comtex SmarTrend(R) - Wed Aug 31, 12:40AM CDT
SmarTrend identified an Uptrend for Douglas Emmett (NYSEEI) on March 2nd, 2016 at $27.90. In approximately 6 months, Douglas Emmett has returned 33.85% as of today's recent price of $37.35.
DEI: 37.78 (+0.03)

Uptrend Call Working As Douglas Emmett Stock Rises 33.0% (DEI)
Comtex SmarTrend(R) - Tue Aug 23, 1:08PM CDT
SmarTrend identified an Uptrend for Douglas Emmett (NYSEEI) on March 2nd, 2016 at $27.90. In approximately 6 months, Douglas Emmett has returned 33.02% as of today's recent price of $37.12.
DEI: 37.78 (+0.03)

Technical Roundup on REIT Stocks -- Global Net Lease, Vornado Realty Trust, Invesco Mortgage Capital, and Douglas Emmett
PR Newswire - Tue Aug 23, 6:50AM CDT
Stock-Callers.com is currently reviewing the following Diversified REITs: Global Net Lease Inc. (NYSE: GNL), Vornado Realty Trust (NYSE: VNO), Invesco Mortgage Capital Inc. (NYSE: IVR), and Douglas Emmett Inc. (NYSE: DEI). These stocks belong in the Financial sector which was narrowly higher in late trading on Monday, August 22, 2016. As per the article stated in NASDAQ, the NYSE Financial Sector Index climbed less than 0.1%, while financial companies in the S&P 500 Index rose about 0.1%. Sign up today and download for free the research reports for the stocks covered today at:
IVR: 15.43 (-0.56), VNO: 103.77 (+0.13), DEI: 37.78 (+0.03), GNL: 8.31 (-0.07)

Douglas Emmett Shares Up 36.0% Since SmarTrend's Buy Recommendation (DEI)
Comtex SmarTrend(R) - Tue Aug 16, 12:33AM CDT
SmarTrend identified an Uptrend for Douglas Emmett (NYSEEI) on March 2nd, 2016 at $27.90. In approximately 6 months, Douglas Emmett has returned 36.03% as of today's recent price of $37.96.
DEI: 37.78 (+0.03)

Downgrade Alert for Douglas Emmett (DEI)
Comtex SmarTrend(R) - Fri Aug 05, 3:16AM CDT
Douglas Emmett (NYSEEI) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $37.58 on volume of 601,000 shares, below average daily volume of 1.1 million. In the past 52 weeks, shares of Douglas Emmett have traded between a low of $24.73 and a high of $38.25 and closed yesterday at $37.58, which is 52% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 1.8%.
DEI: 37.78 (+0.03)

Douglas Emmett Releases Second Quarter 2016 Earnings Results
PR Newswire - Tue Aug 02, 3:52PM CDT
Douglas Emmett, Inc. (NYSE: DEI), a real estate investment trust (REIT), has released its second quarter 2016 financial results by posting its Second Quarter 2016 Earnings Results and Operating Information package to the investor relations section of its website at www.douglasemmett.com/investors.
DEI: 37.78 (+0.03)

CoreSite (COR) Chosen to Expand Paperspace Cloud Platform
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 8:13AM CDT
The data center REIT, CoreSite Realty Corporation (COR), has been chosen by Paperspace to meet the requirements of its newly launched cloud computing platform.
DCT: 49.21 (-0.06), DEI: 37.78 (+0.03), PSB: 112.39 (-0.51), COR: 77.47 (-0.25)

Douglas Emmett Up 21.7% Since SmarTrend Uptrend Call (DEI)
Comtex SmarTrend(R) - Wed Jun 22, 12:43AM CDT
SmarTrend identified an Uptrend for Douglas Emmett (NYSEEI) on March 2nd, 2016 at $27.90. In approximately 4 months, Douglas Emmett has returned 21.73% as of today's recent price of $33.97.
DEI: 37.78 (+0.03)

Prologis Planning Multi-Story Development in South Seattle
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:42AM CDT
Prologis Inc. (PLD) is planning to come up with a multi-story development in South Seattle, according to a business journal.
DCT: 49.21 (-0.06), DEI: 37.78 (+0.03), PSB: 112.39 (-0.51), PLD: 54.50 (+0.11)

Gladstone Commercial Achieves 98.5% Portfolio Occupancy
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:38AM CDT
Gladstone Commercial Corporation (GOOD) disclosed signing of three news leases that has helped the company achieve portfolio occupancy to 98.5%.
DCT: 49.21 (-0.06), GOOD: 19.05 (+0.08), DEI: 37.78 (+0.03), PSB: 112.39 (-0.51)

One Liberty Properties Buys El Paso Distribution Facility
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:37AM CDT
One Liberty Properties, Inc. (OLP) disclosed the acquisition of a distribution facility in El Paso, TX. The company has shelled out $23.7 million for the purchase.
DCT: 49.21 (-0.06), OLP: 25.12 (-0.24), DEI: 37.78 (+0.03), PSB: 112.39 (-0.51)

Uptrend Call Working As Douglas Emmett Stock Rises 19.5% (DEI)
Comtex SmarTrend(R) - Tue Jun 07, 12:36AM CDT
SmarTrend identified an Uptrend for Douglas Emmett (NYSEEI) on March 2nd, 2016 at $27.90. In approximately 3 months, Douglas Emmett has returned 19.51% as of today's recent price of $33.35.
DEI: 37.78 (+0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading